alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › medical-center

medical-center

3 studies tagged medical-center, dated 2025-07-01 to 2026-07-01. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Experience with donanemab over a 1-year period: observations of side effects and compliance from a regional specialty medical center 2026-07-01
  2. Lecanemab over a two-year duration: Key insights from a regional specialty medical center 2026-01-24
  3. Characterizing clinician communication with patients about lecanemab: A qualitative study of clinicians across seven academic medical centers 2025-07-01

Studies

3 studies carry this tag.

Date range

2025 to 2026

Top journals

  • Alzheimer's & dementia (Amsterdam, Netherlands) 1
  • Alzheimer's & dementia (New York, N. Y.) 1
  • The journal of prevention of Alzheimer's disease 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Experience with donanemab over a 1-year period: observations of side effects and compliance from a regional specialty medical center

    ✓ Peer-reviewed alzhub usefulness score 64 out of 100. Alzheimer's & dementia (Amsterdam, Netherlands) 2026-07-01 Treatments

    Donanemab may be safely used in a real-world setting with structured monitoring.

  2. Lecanemab over a two-year duration: Key insights from a regional specialty medical center

    ✓ Peer-reviewed alzhub usefulness score 55 out of 100. The journal of prevention of Alzheimer's disease 2026-01-24 Treatments

    We sought to evaluate the incidence of amyloid-related imaging abnormalities) ARIA and other adverse events associated with lecanemab.

  3. Characterizing clinician communication with patients about lecanemab: A qualitative study of clinicians across seven academic medical centers

    ✓ Peer-reviewed alzhub usefulness score 55 out of 100. Alzheimer's & dementia (New York, N. Y.) 2025-07-01 Treatments

    Preliminary insights about how clinicians communicate tradeoffs can guide future shared decision-making interventions for mAbs.

All topic tags with their study counts